Retatrutide, a novel drug candidate, is being developed for chronic weight management and potentially type 2 diabetes [1]. Phentermine is an established medication used for short-term weight loss [2].
What is Retatrutide and How Does it Work?
Retatrutide is a triple agonist that targets three key metabolic hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon [1]. By activating these receptors, retatrutide aims to reduce appetite, increase energy expenditure, and improve glycemic control [1].
How Does Phentermine Work for Weight Loss?
Phentermine is a stimulant that acts as an appetite suppressant [2]. It influences the central nervous system to reduce hunger, leading to decreased food intake [2].
How Effective is Retatrutide for Weight Loss?
Clinical trials have shown significant weight reduction with retatrutide. In a Phase 2 study, participants taking retatrutide achieved an average weight loss of up to 24% after 48 weeks [1].
How Effective is Phentermine for Weight Loss?
Phentermine is approved for short-term use, typically a few weeks, and is often prescribed alongside diet and exercise. Its effectiveness is generally considered moderate, with average weight loss varying among individuals [2].
What are the Potential Side Effects of Retatrutide?
The most common side effects reported for retatrutide in clinical trials are gastrointestinal, including nausea, vomiting, diarrhea, and constipation [1].
What are the Side Effects of Phentermine?
Common side effects of phentermine include dry mouth, insomnia, nervousness, and constipation [2]. More serious side effects can include increased heart rate and blood pressure [2].
What is the Difference in Development Status Between Retatrutide and Phentermine?
Retatrutide is an investigational drug currently undergoing clinical trials [1]. Phentermine is an FDA-approved medication that has been available for decades [2].
When Might Retatrutide Be Available?
The timeline for retatrutide's availability depends on the successful completion of ongoing clinical trials and subsequent regulatory review [1]. Information on patent expiry and exclusivity for retatrutide can be tracked on resources like DrugPatentWatch.com [3].
Who is Developing Retatrutide?
Retatrutide is being developed by Eli Lilly and Company [1].
Sources
1. Eli Lilly and Company.
2. U.S. Food and Drug Administration.
3. DrugPatentWatch.com